Stock listing
OTC:RNVA Rennova Health, Inc. Stock
Follow Rennova Health, Inc. into a list and get an email when it puts out news.
- Ticker
- OTC:RNVA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Health care services
- Exchange
- OTC
- Currency
- USD
Rennova Health, Inc. on 6ix
- News releases
- 31 in all · newest Sep 9, 2020 · oldest 2017
- Decks
- 19 decks · latest Jul 11, 2017
Team and board
Officers
| Officer | Role |
|---|
| Seamus Lagan | President, Chief Executive Officer, and Director |
|---|
Board
| Director | Role |
|---|
| Gary L. Blum | Director |
|---|
| Seamus Lagan | President, Chief Executive Officer, and Director |
|---|
| Trevor Langley | Director |
|---|
Events
| Quarter | Results |
|---|
| Quarter to Sep 30, 2024 | Nov 18, 2024 |
|---|
| Quarter to Jun 30, 2024 | Aug 13, 2024 |
|---|
| Quarter to Mar 31, 2024 | May 13, 2024 |
|---|
| Q4 2023 | Feb 28, 2024 |
|---|
| Q3 2023 | Nov 14, 2023 |
|---|
| Q2 2023 | Aug 15, 2023 |
|---|
| Q1 2023 | Apr 17, 2023 |
|---|
| Q4 2022 | Mar 1, 2023 |
|---|
| Q3 2022 | Nov 14, 2022 |
|---|
| Q2 2022 | Aug 15, 2022 |
|---|
All 16 quarters
| Quarter | Results |
|---|
| Q1 2022 | May 16, 2022 |
|---|
| Q4 2021 | Mar 2, 2022 |
|---|
| Q3 2021 | Nov 15, 2021 |
|---|
| Q2 2021 | Aug 17, 2021 |
|---|
| Q1 2021 | May 17, 2021 |
|---|
| Q4 2020 | Mar 3, 2021 |
|---|
Open Events
Financials
Annual, in USD
Income statement
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|
| Revenue | 18.7M | 18.7M | 13.0M | 3.22M | 7.20M | 16.0M | 14.5M | 3.09M | 3.34M | 18.4M |
|---|
| Cost of revenue | 7.57M | 7.57M | 6.77M | 5.29M | 11.8M | 15.6M | 11.5M | 2.66M | 3.66M | 12.5M |
|---|
| Gross profit | 11.1M | 11.1M | 6.27M | -2.07M | -4.58M | 449.0K | 3.04M | 424.1K | -321.9K | 5.89M |
|---|
| Research and development | | | | | | | | | 2.07M | 415.5K |
|---|
| Selling, general and administrative | 9.44M | 9.44M | 7.22M | 7.51M | 11.7M | 16.7M | 14.8M | 15.8M | 23.7M | 27.8M |
|---|
| Operating income | 1.37M | 1.37M | -1.41M | -12.5M | -17.2M | -15.7M | -13.1M | -16.1M | -21.5M | -25.3M |
|---|
| Depreciation and amortization | 310.5K | 310.5K | 469.4K | 643.6K | 701.0K | 795.2K | 1.26M | 1.72M | 2.42M | 2.75M |
|---|
| EBITDA | 1.68M | 1.68M | -940.2K | -11.9M | -16.5M | -14.9M | -11.8M | -14.4M | -19.0M | -22.6M |
|---|
| Interest expense | 1.45M | 1.45M | 2.26M | 3.19M | 9.84M | 21.7M | 21.5M | 21.4M | 6.31M | 2.69M |
|---|
| Income before tax | -314.0K | -314.0K | -3.04M | -5.09M | -19.0M | -46.6M | -12.8M | -49.9M | -23.4M | -45.0M |
|---|
| Income tax | 239.8K | | 312.8K | 179.5K | -1.31M | 766.1K | 766.1K | 1.02M | -778.8K | -9.03M |
|---|
| Net income | -7.73M | -7.73M | -3.29M | 5.61M | -18.3M | -48.0M | -14.0M | -55.2M | -32.6M | -36.0M |
|---|
| Earnings per share, basic | -0.00 | -0.00 | -0.00 | 10.22 | -6,113.26 | -47,937.95 | -1,090.72 | | -452.13 | -1,302.66 |
|---|
Balance sheet
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|
| Cash and equivalents | 49.0K | 49.0K | 499.5K | 724.5K | 25.4K | 16.9K | 6.87K | -2.08M | 78.0K | 8.83M |
|---|
| Receivables | 6.65M | 3.09M | 5.41M | 3.59M | 1.92M | 4.21M | 4.44M | 2.91M | 2.93M | 12.0M |
|---|
| Inventory | 198.2K | 198.2K | 242.6K | 280.5K | 445.4K | 614.3K | 453.4K | 236.9K | | 1 |
|---|
| Current assets | 6.94M | 6.94M | 6.36M | 4.72M | 2.72M | 5.35M | 5.12M | 3.39M | 3.22M | 22.0M |
|---|
| Property, plant and equipment | | | | 5.45M | 7.81M | 8.32M | 8.53M | 2.70M | 2.80M | 7.15M |
|---|
| Total assets | 20.3M | 20.3M | 20.6M | 19.6M | 12.3M | 14.7M | 14.2M | 6.29M | 6.48M | 29.4M |
|---|
| Accounts payable | 12.4M | 12.4M | 11.2M | 12.1M | 14.3M | 13.1M | 8.16M | 4.19M | 3.35M | 4.36M |
|---|
| Current liabilities | 42.5M | 42.5M | 49.3M | 46.4M | 59.2M | 83.4M | 44.4M | 24.9M | 19.6M | 17.8M |
|---|
| Long-term debt | | 8.22M | | | 1.20M | | | 3.75M | 0 | 2.90M |
|---|
| Total debt | 11.8M | | 15.1M | 16.1M | 22.0M | 50.2M | | 15.5M | 12.9M | 12.0M |
|---|
| Total liabilities | 57.1M | 57.1M | 49.7M | 46.9M | 61.3M | 83.6M | 53.4M | 41.1M | 21.4M | 30.6M |
|---|
| Shareholders' equity | -36.8M | -36.8M | -29.1M | -27.3M | -49.0M | -68.9M | -39.2M | -34.8M | -14.9M | -1.19M |
|---|
| Shares outstanding | 32.8B | 40.6B | 9.99B | 548.4K | 3.00K | 1.00K | 12.9K | 3 | 72.1K | 27.6K |
|---|
Cash flow
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|
| Cash from operations | 3.39M | 3.39M | -218.3K | -8.91M | -16.9M | -13.5M | -7.68M | -17.7M | -19.9M | -12.6M |
|---|
| Capital spending | -350.9K | -350.9K | -35.2K | -35.2K | -370.9K | -125 | -213.1K | -1.42M | -18.1K | -456.3K |
|---|
| Free cash flow | 3.04M | 3.04M | -253.6K | -8.91M | -17.3M | -13.5M | -7.89M | -19.1M | -19.9M | -13.0M |
|---|
| Cash from investing | -1.53M | | -905.2K | -374.5K | -288.9K | -658.7K | 662.6K | -492.5K | 63.3K | 4.28M |
|---|
| Cash from financing | -2.31M | -2.31M | 898.5K | 9.61M | 17.2M | 14.2M | 7.02M | 18.1M | 11.0M | 14.7M |
|---|
| Dividends paid | | | | -9.00M | | | | -24.5M | -16.3M | -441.3K |
|---|
| Share buybacks | | 0 | -9 | -244 | -684 | -100 | -47 | -6.67K | -8.35M | 9.74M |
|---|
| Change in cash | -450.5K | -450.5K | -225.1K | 699.2K | 8.42K | 10.1K | 6.87K | -70.2K | -8.76M | 6.43M |
|---|
Open Financials
Cap table
Built by 6ix from Rennova Health, Inc.’s releases
- Common shares
- 43,051,322,257
- Fully diluted
- 43,051,322,257
Fully diluted
| Line | Shares |
|---|
| Common shares | 43,051,322,257 |
|---|
Share count over time
| Count | Shares |
|---|
| Nov 22, 2026 | 43,051,322,257 |
|---|
Open Cap table
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|
| Marlene McLennan | Chief Financial Officer · Jul 1, 2018 – Jul 1, 2018 · Past |
|---|
Seamus LaganOther companies: FOXO Technologies Inc. (Chief Executive Officer and Interim Chief Financial Officer · Since at least Sep 10, 2024) | President, Chief Executive Officer, and Director · Since at least Nov 2, 2015 |
|---|
| Trevor Langley | Director · Since at least Nov 5, 2026 |
|---|
| Benjamin Frank | Director · Nov 2, 2015 – Jul 17, 2016 · Past |
|---|
| Gary L. Blum | Director · Since at least Nov 5, 2026 |
|---|
| Jason Adams | Chief Financial Officer · Nov 2, 2015 – Jul 17, 2016 · Past |
|---|
| Kamran Ajami | Director · Apr 9, 2017 – Mar 6, 2018 · Past |
|---|
| Michael Louis Goldberg | Director · May 2, 2016 – Jul 17, 2016 · Past |
|---|
| Samuel R Mitchell Jr | Chief Operating Officer · Nov 2, 2015 – Nov 2, 2015 · Past |
|---|
| Smruti J Vidwans | Chief Science Officer · Nov 2, 2015 – Nov 2, 2015 · Past |
|---|
Open People
Log in to ask 6ix AI your own questions about Rennova Health, Inc.